Press releases

Angelini Pharma announces that the European Commission (EC) has approved the extension of the indication of Xydalba® (dalbavancin) for the treatment of acute bacterial skin and soft tissue infections in children.

Jacopo Andreose, who will take on the role from February 6, has over twenty years of experience in top management positions in the pharmaceutical industry.

Ukraine–Russia conflict and climate change may lead to a new wave of mental health disorders in the coming months.

In his position, Manarini will report hierarchically to the CEO, Pierluigi Antonelli and will join the Leadership Team-the executive committee-of Angelini Pharma.

The report highlights the need for closer European collaboration to tackle the burden of epilepsy

Rafal Kaminski has broad international experience in drug discovery and innovation and will lead Angelini Pharma’s research and development (R&D) strategy. He will commence his role in January 2022.

The COVID 19 pandemic has exacerbated gender-related challenges with its mental health consequences disproportionately affecting women, both at work and at home.

The fund has been established to invest in early-stage companies in Canada and U.S. markets, that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases.

Angelini Pharma announced today that the EC has granted marketing authorization for ONTOZRY®.

Four thousand European citizens were interviewed by SWG on behalf of Angelini Pharma on the occasion of the Purple Day, the international day of awareness about epilepsy. According to the majority of respondents, people with epilepsy are perfectly normal people, but 40% would not talk about the disease at work.